Premium
Long‐term consequences of perinatal fatty acid amino hydrolase inhibition
Author(s) -
Wu ChiaShan,
Morgan Daniel,
Jew Chris P,
Haskins Chris,
Andrews MaryJeanette,
Leishman Emma,
Spencer Corinne M,
Czyzyk Traci,
Bradshaw Heather,
Mackie Ken,
Lu HuiChen
Publication year - 2014
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.12500
Subject(s) - fatty acid amide hydrolase , anandamide , endocannabinoid system , offspring , neurogenesis , medicine , endocrinology , fatty acid , psychology , anxiety , omega 3 fatty acid , cannabinoid receptor , physiology , pregnancy , neuroscience , chemistry , docosahexaenoic acid , biology , biochemistry , psychiatry , polyunsaturated fatty acid , antagonist , receptor , genetics
Fatty acid amide hydrolase inhibitors show promise as a treatment for anxiety, depression and pain. Here we investigated whether perinatal exposure to URB597, a fatty acid amide hydrolase inhibitor, alters brain development and affects behaviour in adult mice.